1. van der Putten AB, Bijleveld CM, Slooff MJ, Wesenhagen H, Gips CH. Selection criteria and decisions in 375 patients with liver disease, considered for liver transplantation during 1977-1985. Liver. 1987; 7:84–90.
2. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 con-secutive patients. Ann Surg. 1988; 207:373–379.
3. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993; 218:145–151.
Article
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334:693–699.
Article
5. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Trasnpl. 2002; 8:765–774.
Article
6. Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008; 14:935–945.
Article
7. Kwon CH, Kim DJ, Han YS, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis. 2007; 25:313–319.
Article
8. Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU. Liver trnasplantation for hepatocellular carcinoma in patients who do not meet Milan criteria. Dig Dis. 2007; 25:329–333.
9. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007; 13:1637–1644.
Article
10. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007; 25:310–312.
Article
11. Soejima Y, Taketomi A, Yoshizumi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation. 2007; 83:893–899.
Article
12. Lee SG, Ahn CS, Ha TY, et al. Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Surg. 2009. [Epub ahead of print].
13. Moon DB, Lee SG. Liver transplantation. Gut and liver. 2009; 3:145–165.
Article
14. Moon DB, Lee SG, Hwang S. Liver transplantation for hepatocellular carcinoma: single nodule with Child-Pugh class A sized less than 3 cm. Dig Dis. 2007; 25:320–328.
Article
15. Gondolesi GE, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patient hepatocellular carcinoma: ex-tending UNOS priority criteria. Ann Surg. 2004; 239:142–149.
16. Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation. Liver Transpl. 2004; 10:440–447.
17. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early ir-resectable hepatocellular carcinoma. Br J Surg. 2007; 94:78–86.
Article
18. Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living donor liver transplantation? -no, never. J Hepatol. 2005; 43:573–577.
19. Marcos A, Fisher RA, Ham JM, et al. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation. 2000; 69:1375–1379.
20. Drixler TA, Vogten MJ, Ritchie ED, et al. Liver regeneration is anangiogenesis-associated phenomenon. Ann Surg. 2002; 236:703–712.
21. Todo S, Furukawa H: The Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004; 240:451–459.
22. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl. 2005; 11:1265–1272.
Article
23. Hwang S, Lee SG, Belghiti J. Liver transplantation for HCC: its role. Eastern and western perspectives. J Hepatobiliary Pancreat Surg. 2009. (Epub ahead of print).
24. Yao FY, Ferrel L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33:1394–1403.
Article
25. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from waiting list. Liver Transpl. 2002; 8:873–883.
26. Furukawa H, Shimamura T, Suzuki T, et al. Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Surg. 2009. [Epub ahead of print].
Article
27. Trotter JF, Adam R, Lo CM, Kenison J. Documented deaths of hepatic lobe donors for living donor liver transplantation. Liver Transpl. 2006; 12:1485–1488.
Article
28. Lo CM, Fan ST, Liu CL, et al. Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg. 2004; 240:151–158.
Article
29. Hwang S, Lee SG, Lee YJ, et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl. 2006; 12:920–927.
Article
30. Marsh JW, Gray E, Ness R, Starzl TE. Complications of right lobe living donor liver transplantation. J Hepatol. 2009; 51:715–724.
Article
31. Bruix J, Fuster J, Llovet JM. Liver transplantation for hepto-cellular carcinoma: foucault pendulum versus evidence-based decision. Liver Transpl. 2003; 9:700–702.
32. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment for moderately and well-differentiated hepatocellular carcinoma. Ann Surg. 2004; 239:150–159.
33. Marshall AE, Rushbrook SM, Voeler SL, et al. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl. 2010; 16:279–288.
Article
34. Durand F, Regimbeau JM, Belghiti J, et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol. 2001; 35:254–258.
Article
35. Perkins JD. Seeding risk following percutaneous approach to hepatocellular carcinoma. Liver Transpl. 2007; 13:1603–1607.
Article
36. Han K, Tzimas GN, Barkun JS, et al. Preoperative alphafetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol. 2007; 21:39–45.
Article
37. Nanashima A, Morino S, Yamaguchi H, et al. Modified CLIP using PIVKA-II for evaluating prognosis after hepatoctomy for hepatocellular carcinoma. Eur J Surg Oncol. 2003; 29:735–742.
38. Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des- gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009; 87:531–537.
39. Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006; 30:1736–1741.
Article
40. Yang SH, Suh KS, Lee HW, et al. The role of (18)F-FDG- PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl. 2006; 12:1655–1660.
41. Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alphafetoprotein level to expand candidates for living donor liver transplantation in hepatocellular carcinoma. Surgery. 2007; 141:598–609.
42. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to over-come drug resistance in the clinic. Biochim Biophys Acta. 2009; 1796:75–90.
Article
43. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40:667–676.
Article
44. Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation. 2005; 80(suppl 1):S113–S119.
Article
45. Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008; 48:819–827.
Article
46. Soderdahl G, Backman L, Isoniemi H, et al. A prospective, randomized, multicentre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int. 2006; 19:288–294.
Article
47. Porrett PM, Peterman H, Rosen M, et al. Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl. 2006; 12:665–673.
Article
48. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2005; 11:767–775.
Article
49. Perez Saborido B, Meneu JC, Moreno E, et al. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg. 2005; 190:383–387.
50. Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg. 2003; 238:508–519.
51. Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver resection for hepatocellular carcinoma. Ann Surg. 2003; 238:885–893.
52. Hwang S, Lee SG, Moon DB, et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl. 2007; 13:741–746.
Article
53. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma aftre liver transplantation. J Clin Oncol. 1999; 17:324–331.
54. Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer. 1991; 68:2095–2100.
Article
55. Kornberg A, Kü pper B, Tannapfel A, et al. Longterm survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol. 2010; 36:275–280.
Article
56. Taketomi A, Fukuhara T, Morita K, et al. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol. 2010. [Epub ahead of print].
Article
57. Valdivieso A, Bustamante J, Gastaca M, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc. 2010; 42:660–662.
Article
58. Roayaie S, Schwarts JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns of prognosis. Liver Transpl. 2004; 10:534–540.
59. Lee JO, Kim DY, Lim JH, et al. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol. 2009; 24:800–805.
Article
60. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 2005; 11:497–503.
Article
61. Vivarelli M, Cuccetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008; 248:857–862.
62. Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009; 135:715–722.
Article
63. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus- based immunosuppression after liver transplantation for hepatocellular carcinoma: longterm outcomes and side effects. Transplantation. 2007; 83:1162–1168.